catalyst
pharmaceuticals
announces
issuance
patent
coral
gables
globe
newswire
catalyst
pharmaceuticals
catalyst
nasdaq
cprx
biopharmaceutical
company
focused
developing
commercializing
innovative
therapies
people
rare
debilitating
chronic
neuromuscular
neurological
diseases
today
announced
united
states
patent
trademark
office
uspto
issued
new
patent
catalyst
pharmaceuticals
amifampridine
patent
methods
administering
expiring
april
pleased
patent
amifampridine
issued
believe
create
significant
barriers
therapeutically
equivalent
generic
competition
entering
market
approximately
nine
years
beyond
orphan
drug
exclusivity
said
patrick
mcenany
chairman
chief
executive
officer
catalyst
mcenany
added
remain
committed
serving
neuromuscular
community
continuing
investigate
rare
neurodegenerative
diseases
also
look
forward
results
various
trials
positive
strengthen
value
proposition
use
patent
directed
innovative
methods
administering
amifampridine
slow
metabolizers
amifampridine
commented
steven
miller
chief
operating
officer
chief
scientific
officer
catalyst
miller
added
within
next
days
intend
submit
request
fda
patent
listed
approved
drug
products
therapeutic
equivalence
evaluations
commonly
known
fda
orange
book
published
united
states
food
drug
amifampridine
extensively
metabolized
transferase
type
rate
metabolism
quite
variable
patients
patent
directed
use
suitable
doses
amifampridine
treat
patients
regardless
therapeutic
indication
slow
metabolizers
amifampridine
drug
product
containing
amifampridine
label
states
patented
dosing
regimens
doses
dosing
administration
section
prior
could
possibly
infringe
patent
generic
drug
product
labels
would
necessarily
catalyst
would
take
appropriate
action
protect
intellectual
property
amifampridine
mg
tablets
oral
nonspecific
potassium
channel
blocker
causes
depolarization
presynaptic
membrane
slows
inhibits
repolarization
action
results
opening
slow
calcium
channels
allowing
subsequent
influx
turn
induces
exocytosis
synaptic
vesicles
containing
acetylcholine
ach
release
ach
synaptic
cleft
enhancing
neuromuscular
transmission
providing
improved
muscle
function
catalyst
pharmaceuticals
catalyst
pharmaceuticals
biopharmaceutical
company
focused
developing
commercializing
innovative
therapies
people
rare
debilitating
chronic
neuromuscular
neurological
diseases
including
myasthenic
syndrome
lems
antibody
positive
myasthenia
gravis
spinal
muscular
atrophy
sma
type
catalyst
new
drug
application
amifampridine
mg
tablets
treatment
adults
lems
approved
november
food
drug
administration
fda
firdapse
commercially
available
united
states
canada
national
healthcare
regulatory
agency
health
canada
recently
approved
use
amifampridine
treatment
patients
canada
lems
firdapse
currently
evaluated
clinical
trials
treatment
sma
type
received
orphan
drug
designation
fda
myasthenia
gravis
statements
press
release
contains
statements
statements
involve
known
unknown
risks
uncertainties
may
cause
catalyst
actual
results
future
periods
differ
materially
forecasted
results
number
factors
including
scope
protection
competition
provided
patent
ii
factors
described
catalyst
annual
report
form
fiscal
year
filings
securities
exchange
commission
sec
could
adversely
affect
catalyst
copies
catalyst
filings
sec
available
sec
may
found
catalyst
website
may
obtained
upon
request
catalyst
catalyst
undertake
obligation
update
information
contained
herein
speaks
date
investor
contact
brian
korb
solebury
trout
company
contact
patrick
mcenany
catalyst
pharmaceuticals
chief
executive
officer
media
contact
david
schull
russo
partners
